A randomized, split-face, comparative clinical study on the efficacy of Eucerin ultraWHITE+ spotless and the combination of 2%hydroquinone and 4%arbutin for the treatment of skin hyperpigmentation

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190614008

Enrollment

Registered

2019-06-14

Start date

2019-03-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epidermal melasma

Interventions

The product contains Thiamidol as an active ingredient,2%hydroquinone and 4%arbutin

Experimental Drug,Active Comparator Drug

Eucerin ultraWHITE+ spotless,2%hydroquinone and 4%arbutin

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: participants with epidermal melasma

Exclusion criteria

Exclusion criteria: -subjects who receive any topical treatment within 2 weeks or laser treatment within 3 months -pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Skin lightness (L) week 0,4,8,12 multi-probe adapter system Cutometer dual MPA580	—

Secondary

Measure	Time frame
clinical grading week 0,4,8,12 photograph	—

Countries

Thailand

Contacts

Public ContactRatchathorn Panchaprateep

Faculty of Medicine, Chulalongkorn University

rpanchaprateep@gmail.com0898923819

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

A randomized&#44; split&#45;face&#44; comparative clinical study on the efficacy of Eucerin ultraWHITE+ spotless and the combination of 2%hydroquinone and 4%arbutin for the treatment of skin hyperpigmentation